Daiichi Sankyo Licenses ERS Genomics’ CRISPR Gene Editing Tech

January 31, 2020
Pharmaceutical Technology Editors

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletter, Pharmaceutical Technology\'s In the Lab eNewsletter-02-05-2020, Volume 15, Issue 2

The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.

Japan-based pharmaceutical company Daiichi Sankyo has signed a license agreement with Ireland-based biotechnology company ERS Genomics for ERS Genomics’ CRISPR/Cas9 genome-editing technology intellectual property for use in internal R&D. The agreement was announced on Jan. 13, 2020, and financial terms were not disclosed. 

ERS Genomics holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications except for use as a human therapeutic. Under the agreement, Daiichi Sankyo is able to use CRISPR technology to support its R&D initiatives to address areas of unmet medical need.

“Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations,” said Eric Rhodes, CEO of ERS Genomics, in a company press release.

Source: ERS Genomics